Welcome to CDC stacks | Risk of myeloid neoplasms after solid organ transplantation - 41988 | CDC Public Access
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Risk of myeloid neoplasms after solid organ transplantation
  • Published Date:
    Apr 14 2014
  • Source:
    Leukemia. 28(12):2317-2323.
Filetype[PDF-1.10 MB]


Details:
  • Pubmed ID:
    24727673
  • Pubmed Central ID:
    PMC4197126
  • Description:
    Solid organ transplant recipients have elevated cancer risks, owing in part to pharmacologic immunosuppression. However, little is known about risks for hematologic malignancies of myeloid origin. We linked the US Scientific Registry of Transplant Recipients with 15 population-based cancer registries to ascertain cancer occurrence among 207 859 solid organ transplants (1987-2009). Solid organ transplant recipients had a significantly elevated risk for myeloid neoplasms, with standardized incidence ratios (SIRs) of 4.6 (95% confidence interval 3.8-5.6; N=101) for myelodysplastic syndromes (MDS), 2.7 (2.2-3.2; N=125) for acute myeloid leukemia (AML), 2.3 (1.6-3.2; N=36) for chronic myeloid leukemia and 7.2 (5.4-9.3; N=57) for polycythemia vera. SIRs were highest among younger individuals and varied by time since transplantation and organ type (Poisson regression P<0.05 for all comparisons). Azathioprine for initial maintenance immunosuppression increased risk for MDS (P=0.0002) and AML (2-5 years after transplantation, P=0.0163). Overall survival following AML/MDS among transplant recipients was inferior to that of similar patients reported to US cancer registries (log-rank P<0.0001). Our novel finding of increased risks for specific myeloid neoplasms after solid organ transplantation supports a role for immune dysfunction in myeloid neoplasm etiology. The increased risks and inferior survival should heighten clinician awareness of myeloid neoplasms during follow-up of transplant recipients.

  • Document Type:
  • Collection(s):
  • Funding:
    HHSN261201000037C/CA/NCI NIH HHS/United States
    HHSN261201000027C/CA/NCI NIH HHS/United States
    ZIA CP010170-11/Intramural NIH HHS/United States
    N01PC35143/CA/NCI NIH HHS/United States
    U58 DP000805/DP/NCCDPHP CDC HHS/United States
    U58 DP000817/DP/NCCDPHP CDC HHS/United States
    HHSN261201000035C/CA/NCI NIH HHS/United States
    P30 ES005605/ES/NIEHS NIH HHS/United States
    P30 CA086862/CA/NCI NIH HHS/United States
    HHSN261201000036C/CA/NCI NIH HHS/United States
    N01PC35137/CA/NCI NIH HHS/United States
    U58 DP000807/DP/NCCDPHP CDC HHS/United States
    U58 DP000808/DP/NCCDPHP CDC HHS/United States
    N01PC35142/CA/NCI NIH HHS/United States
    Z99 CA999999/Intramural NIH HHS/United States
    HHSN261201000035I/CA/NCI NIH HHS/United States
    U58 DP000848/DP/NCCDPHP CDC HHS/United States
    U58 DP000812/DP/NCCDPHP CDC HHS/United States
    HHSN261201000024C/CA/NCI NIH HHS/United States
    HHSN261201000034C/CA/NCI NIH HHS/United States
    N01PC54405/CA/NCI NIH HHS/United States
    U58 DP000832/DP/NCCDPHP CDC HHS/United States
    N01PC35139/CA/NCI NIH HHS/United States
    HHSN261201000026C/CA/NCI NIH HHS/United States
    U58 DP000824/DP/NCCDPHP CDC HHS/United States
No Related Documents.
You May Also Like: